CD8A and neoplasm: Finally, a DNA vaccine encoding the prostate tumor antigen SSX-2 was found to increase the expression of PD-1 on vaccine-activated CD8+ T cells following vaccination, and the efficacy of this vaccine could be increased in tumor-bearing mice when combined with PD-1 or PD-L1 blockade [112].